In Brief HIV infection results in global changes to the cellular proteome. Greenwood et al. show that one HIV protein, Vpr, is directly or indirectly responsible for almost all of these changes by targeting multiple proteins for degradation. This broad substrate specificity explains the difficulties to date in understanding this enigmatic protein.
INTRODUCTION
The HIV-1 ''accessory proteins'' Vif, Vpr, Vpu, and Nef function by binding host proteins and recruiting them to cellular degradation machinery, resulting in depletion of these target substrates Simon et al., 2015; Sugden et al., 2016; Sumner et al., 2017) . Some targets of Vif, Vpu, and Nef, such as APOBEC3 family members, Tetherin, and SERINC3/ SERINC5, are dominantly acting viral restriction factors, and their degradation is therefore thought to directly enhance in vivo viral replication. Conversely, the role of Vpr in enhancing viral replication remains unclear.
Unlike other accessory proteins, Vpr is packaged into nascent viral particles and delivered into newly infected cells, and it is therefore present in the earliest stages of the viral replication cycle. Although Vpr does not enhance in vitro viral replication in most experimental systems, a number of cellular phenotypes have been ascribed to it; it has been described as an ''enigmatic multitasker'' (Guenzel et al., 2014) . For example, expression of Vpr has variously been reported to cause arrest of cycling cells at the G2/M phase, apoptosis, enhancement of HIV gene expression, and stimulation or inhibition of key signaling pathways such as nuclear factor kB (NF-kB) and nuclear factor of activated T cells (NFAT) (Ayyavoo et al., 1997; Felzien et al., 1998; Lahti et al., 2003; Re et al., 1995; Roux et al., 2000) .
Although the mechanisms by which Vpr causes such complex effects is controversial, most reports agree that they depend on Vpr interacting with a cellular E3 ligase complex containing DCAF1, DDB1, and Cul4 (Dehart and Planelles, 2008; Le Rouzic et al., 2007) . As with the other accessory proteins, Vpr is therefore presumed to function by recruiting cellular factors to this E3 ligase complex, resulting in their subsequent degradation. Accordingly, several host factors depleted by Vpr have been identified, but their connection to Vpr-associated cell biological phenotypes is generally unclear, as is their role in regulating viral replication in vivo (Hofmann et al., 2017; Hrecka et al., 2016; Laguette et al., 2014; Lahouassa et al., 2016; Lv et al., 2018; Maudet et al., 2013; Romani et al., 2015; Schrö felbauer et al., 2005; Zhou et al., 2016) .
We previously used unbiased quantitative proteomics to map temporal changes in cellular protein abundance during HIV infection of CEM-T4 T cells and identify targets of Vpu (SNAT1), Nef (SERINC3/5), and Vif (PPP2R5A-E) Matheson et al., 2015) . Nonetheless, known accessory protein targets only account for a tiny fraction of all HIVdependent protein changes observed in our experiments . Given the varied cell biological phenotypes ascribed to Vpr, we hypothesized that it may be responsible for some of the remaining changes. Therefore, in this study, we undertake a comprehensive analysis of the effects of Vpr on the cellular proteome of HIV-1-infected cells and combine this with further unbiased approaches to identify cellular proteins directly targeted and degraded by Vpr. Our data suggest a model for the effects of Vpr on cells in which promiscuous targeting of host factors distinguishes it from other HIV accessory proteins.
RESULTS

Vpr Is Required for Global Proteome Remodeling in HIV-Infected Cells
First, we compared total proteomes of uninfected CEM-T4 T cells with cells infected with either wild-type (WT) HIV or an HIV Vpr deletion mutant (HIV DVpr) at an infectious MOI of 1.5 ( Figure 1A ), resulting in approximately 75% infection ( Figure 1B ). Data from this experiment are available, together with the other proteomics datasets presented here, in a readily searchable interactive format in Table S1 . As expected, among the 7,774 quantitated proteins, we observed widespread changes in cells infected with wild-type HIV (Figure 1C left panel) . Together with known Nef, Vpu, and Vif targets, we saw depletion of previously reported Vpr targets, including HLTF (Hrecka et al., 2016; Lahouassa et al., 2016) , ZGPAT (Maudet et al., 2013) , MCM10 (Romani et al., 2015) , UNG (Schrö felbauer et al., 2005) , TET2 (Lv et al., 2018) , and MUS81 and EME1 (Laguette et al., 2014; Zhou et al., 2016) . DCAF1, part of the ligase complex used by Vpr to degrade targets, was also depleted, consistent with a previous report (Lapek et al., 2017) . Table S1 .
In HIV DVpr infection ( Figure 1C , right panel), depletion of Nef, Vpu, and Vif targets was maintained. Remarkably, as well as abolishing depletion of known Vpr targets, almost all of the previously uncharacterized protein changes were also reduced or abolished in HIV DVpr infection. Although 1,940 proteins changed significantly (q < 0.01) in wild-type HIV-infected cells, only 45 significant changes occurred in cells infected with HIV DVpr. Indeed, principal-component analysis showed that cells infected with the HIV DVpr virus are more similar on the proteome level to uninfected cell than to cells infected with the wild-type virus ( Figure 1D ).
Incoming Vpr Protein Alone Drives Global Cellular Proteome Remodeling
Because Vpr enhances the expression of other viral proteins (Forget et al., 1998; Goh et al., 1998 ; Figure 1C ), differences between wild-type and DVpr viruses could potentially be explained by secondary changes in expression levels of other proteins or different rates of progression of wild-type and DVpr viral infection. To eliminate these potential confounders, we next examined the effect of Vpr acting alone. Unlike other HIV-1 accessory proteins, Vpr is specifically packaged into nascent viral particles. We therefore repeated our proteomics analysis using CEM-T4 T cells exposed to lentiviral particles lacking or bearing Vpr in the presence of reverse transcriptase inhibitors (RTis). This approach excludes all de novo viral protein expression, focusing on changes induced by incoming Vpr delivered directly by virions ( Figure 2A ). For these experiments, cells were exposed to viral particles at an infectious MOI of 0.5 (determined in the absence of RTis). Strikingly, changes induced by Vpr-containing viral particles phenocopied the Vpr-dependent proteome remodeling seen in HIV infection ( Figure 2B ) with a high degree of correlation (r 2 = 0.67; Figure 2C ). Taking both experiments together, Vpr is both necessary and sufficient to cause significant (q < 0.01) depletion of at least 302 proteins and upregulation of 413 (highlighted in blue and red, respectively, in Figure 2C ). This is a stringent false discovery rate, and, in practice, the number of Vpr-dependent changes is almost certainly even higher. Where antibodies were available, we confirmed a proportion of these changes by immunoblot ( Figure 2D ).
Cellular Proteome Remodeling Requires Interaction with DCAF1 and Cellular Substrates
Although the function or functions of Vpr remain controversial, in all phenotypic descriptions, Vpr activity is dependent on the interaction between Vpr and the DCAF1/DDB1/Cul4 ligase complex, recruitment of which results in ubiquitination and degradation of known Vpr targets by the ubiquitin-proteasome system (Dehart and Planelles, 2008) . Therefore, in addition to testing the effect of wild-type Vpr protein, we tested a number of previously described mutant Vpr variants (Figure 2A ). Figure 2E shows an immunoblot of the Vpr protein delivered in the viral particles (top panel) and the abundance of Gag-Pol peptides in the cellular lysate at 48 h determined from the tandem mass tag (TMT) mass spectrometry (MS) experiment. Incoming Vpr alone was sufficient to cause arrest at G2/M, as described previously (Poon et al., 1998) , and Figure 2F shows 7-aminoactinomycin D (7-AAD) DNA staining to determine the extent of G2/M arrest under each condition. Visualizations of the proteome remodeling caused by each mutant are shown in Figures 2G and 2H .
Because the Q65 residue of Vpr is required for the interaction with DCAF1 (Le Rouzic et al., 2007) , we first compared proteome changes caused by a Q65R Vpr mutant with wild-type Vpr. As predicted, Q65R Vpr was almost completely inactive (Figures 2G and 2H) . We recapitulated this finding by comparing the effects of wild-type Vpr in control cells or cells depleted of DCAF1 ( Figure S1A ). Short hairpin RNA (shRNA)-mediated depletion of DCAF1 resulted in an approximately 50% reduction in protein abundance of DCAF1 ( Figure S1B ). Because a proportion of cellular DCAF1 was still expressed, known Vpr effects, including degradation of HLTF and upregulation of CCNB1, were partially rather than completely inhibited ( Figure S1C ). Consistent with this, Vpr-mediated changes were broadly reduced in magnitude in DCAF1 knockdown cells ( Figure S1D ). Thus, as with depletion of known Vpr targets, extensive Vpr-dependent proteomic remodeling is dependent on the interaction of Vpr with its cognate DCAF1/DDB/Cul4 ligase. Importantly, depletion of DCAF1 alone did not phenocopy Vpr-mediated proteome remodeling, and the widespread effects of Vpr are therefore unlikely to result from sequestration and/or depletion of DCAF1.
Residues E24, R36, Y47, D52, and W54 of Vpr are also required for recruitment and degradation of previously described Vpr targets and have been reported to form the substrate-binding surface (Hrecka et al., 2016; Selig et al., 1997; Wu et al., 2016) . In particular, Y47, D52, and W54 make up the proposed DNA-mimicking motif by which Vpr binds the cellular target UNG2 (Wu et al., 2016) . In agreement, the Vpr E24R, R36P and Vpr W54R mutants showed attenuated remodeling of the proteome, whereas a triple mutant, Vpr Y47A, D52A, W54R , was defective for almost all Vpr-dependent protein changes (Figures 2G and 2H) . Global protein remodeling therefore depends on both the substrate binding surfaces of Vpr and recruitment of DCAF1, suggesting that this process is mediated by recruitment of Vpr substrates to the DCAF1/DDB1/CUL4 E3 ligase complex and their subsequent degradation.
Vpr causes G2/M arrest in cycling cells, but the mechanism remains contentious Berger et al., 2015; Fregoso and Emerman, 2016; Goh et al., 1998; Hö hne et al., 2016; Laguette et al., 2014; Liang et al., 2015; Re et al., 1995; Romani et al., 2015; Terada and Yasuda, 2006) , as is the connection to the replicative advantage Vpr provides in vivo. To investigate this important issue, we took advantage of previously characterized Vpr mutants. Residue S79 of Vpr is required for Vpr-dependent cell cycle arrest (Zhou and Ratner, 2000;  Figure 2F ). Of the other mutants we tested, Vpr Q65R and Vpr Y47A, D52A, W54R are also unable to cause G2/M arrest, Vpr E24R, R36P had an intermediate phenotype, and Vpr W54R caused G2/M arrest at wild-type levels ( Figure 2F ). Strikingly, most Vpr-dependent protein changes were also observed with the Vpr S79A mutant (Figures 2G and 2H) and are therefore independent of G2/M cell cycle arrest. The presence or absence of G2/M arrest was also a poor correlate of proteomic remodeling across the entire panel of mutants. Cell cycle arrest therefore only explains a minority of Vpr-dependent changes ( Figures 2G and 2H) . To confirm this finding, we examined published datasets describing proteins increased or depleted during different phases of the cell cycle or in chemically G2/M-arrested cells (Fischer et al., 2016; Ly et al., 2015;  Figure S2 ). Compared with cells exposed to Vpr in our study, cells arrested in G2 using a PLK1 inhibitor showed similar regulation of the cyclin family of proteins ( Figure S2B ), but there was little other correlation between these datasets. Thus, although some changes in protein levels induced by Vpr may be explained by the effects of cell cycle arrest, proteins regulated by the cell cycle in these datasets only account for a minority of Vpr-dependent changes ( Figures  S2A, S2C , and S2D).
Vpr Directly Targets Multiple Nuclear Proteins with Nucleic Acid Binding Activity Vpr has nuclear localization, and all reported direct Vpr targets are nuclear proteins. Primary Vpr targets are therefore predicted to be nuclear. Conversely, secondary effects resulting from, for example, transcriptional changes should be distributed across the cell. Analysis of the 302 proteins depleted by Vpr revealed profound enrichment for proteins that reside in the nucleus (>80%) ( Figure 3A, left) . This raised the possibility that a significant proportion of proteins depleted by Vpr are directly targeted by Vpr because secondary effects should not be limited to the nucleus. Consistent with this hypothesis, proteins upregulated by Vpr ( Figure 3A , right), which are all predicted to be secondary indirect effects, were distributed across multiple compartments. Furthermore, proteins depleted by Vpr were enriched (>70%) for nucleic acid binding activity ( Figure 3B , left). Vpr associates with DNA-binding proteins such as UNG via a substrate-binding surface that mimics DNA (Wu et al., 2016) . Thus, rather than targeting a small number of cellular proteins for degradation, Vpr may have a much wider range of direct targets, and the structure of the substrate binding surface suggests a possible mechanism for promiscuous recruitment of DNA-and RNA-binding cellular proteins.
To identify proteins targeted directly by Vpr, we first adopted a co-immunoprecipitation approach ( Figure 3C ). CEM-T4 T cells were transduced with a 33 hemagglutinin (HA)-tagged Vpr lentivirus in the presence of an shRNA to DCAF1 and the pan-cullin inhibitor MLN4924 to minimize substrate degradation and enhance co-immunoprecipitation. Factors specifically co-immunoprecipitated in the presence of Vpr are expected to include direct Vpr targets and, accordingly, were enriched for proteins depleted (rather than increased) in the presence of Vpr ( Figures  3D-3G) . However, the co-immunoprecipitation (coIP) was dominated by DCAF1, a stable binding partner of Vpr, identified with a signal intensity 2 orders of magnitude greater than that of all other proteins ( Figure 3E ). This is despite knockdown of DCAF1 in these cells, which reduces the DCAF1 protein abundance by approximately 50% ( Figure S2B ). In addition, at least 13 proteins co-immunoprecipitating with Vpr here have been reported previously to physically interact with DCAF1 alone (Coyaud et al., 2018; Guo et al., 2016; Hossain et al., 2017) , of which 11 are not regulated by Vpr, and two, CEP78 and IQGAP2, are upregulated by Vpr, explaining their presence in this list of proteins.
This mismatch between the high abundance of DCAF1 and the relatively low abundance of direct Vpr targets for degradation is consistent with previous reports that have also found that IP-MS based techniques are ideal for identification of the cellular machinery co-opted by viral proteins but often struggle to identify cellular targets that interact transiently and in competition with each other (Jä ger et al., 2011; Luo et al., 2016) . We therefore adopted an alternative approach, pulsed-stable isotope labeling with amino acids in cell culture (pulsed SILAC), to identify host proteins specifically destabilized within 6 h of exposure to Vpr ( Figure 4A ). This technique is directly analogous to a traditional pulse-chase experiment using radiolabeled methionine and/or cysteine but allows a global unbiased analysis of potential cellular targets (Boisvert et al., 2012) . Because proteins are fully labeled prior to exposure to Vpr, differences in abundance of labeled proteins between conditions exclusively reflect changes in protein degradation rates.
Six hours after exposure to Vpr, the stability of most proteins was unchanged ( Figure 4B , top panel). However, a subset of proteins depleted by Vpr was already destabilized, consistent with Vpr-dependent proteasomal degradation. Therefore, these 27 proteins, including HLTF, represent direct targets for Vpr-mediated depletion ( Figure 4C ). After 24 h of exposure to Vpr, Combining all orthogonal approaches-whole cell proteomics to identify proteins depleted by Vpr in the context of viral infection or Vpr protein alone delivered in viral particles, MS coIP with epitope-tagged Vpr, and pulsed SILAC-based identification of proteins post-translationally degraded by Vpr-we identified at least 38 direct targets for Vpr-dependent degradation (Table 1) . Vpr is both necessary and sufficient for depletion of these proteins, which are either bound by Vpr, or destabilized within 6 h of Vpr exposure (or both). In practice, this list very likely underestimates the true number of direct Vpr targets because several known targets of Vpr behaved appropriately but beyond the statistical cutoffs used to derive this table (Table S2) . Table 1 is also limited to proteins expressed in the CEM-T4 T cell model, which excludes some known Vpr targets such as SMUG1 (Schrö felbauer et al., 2005) . It should be noted that some cellular phenotypes for Vpr are exclusive to non-T cell targets, such as primary dendritic cells (Miller et al., 2017) and macrophages (Connor et al., 1995; Mashiba et al., 2015) , and are unlikely to be explained by Vpr-mediated depletion of any of the proteins listed here.
The Direct Vpr Targets SMN1, CDCA2, and ZNF267 Contribute to G2/M Cell Cycle Arrest Several cellular phenotypes have been described for Vpr, including G2/M arrest, transactivation of the HIV long terminal repeat (LTR), and modulation of cellular signaling pathways such as NFkB and NFAT arrest (Bolton and Lenardo, 2007; Gummuluru and Emerman, 1999; Hö hne et al., 2016; Liang et al., 2015; Liu et al., 2014; Muthumani et al., 2006; Rogel et al., 1995) . The mechanisms responsible for these phenotypes are controversial. Wide-scale proteome remodeling by Vpr and direct targeting of multiple proteins suggest a model in which Vpr interacts with diverse cellular proteins and pathways, resulting in cumulative or redundant effects on cellular phenotypes. This model does not contradict any single mechanism but suggests that several are involved, with potential variability between different cell types and experimental systems.
To test our model, we investigated the best-described phenotype for Vpr, cell cycle arrest at the G2/M phase. We hypothesized that differential depletion of cellular proteins by different Vpr mutants tested in Figure 2 , which displayed a spectrum of capacity to cause G2/M arrest, would highlight proteins whose depletion results in this cellular phenotype. We first examined proteins with a published connection to Vpr-mediated G2/M arrest: MCM10, MUS81, and EME1. MCM10 has been reported to be directly degraded by Vpr, resulting in cell cycle arrest (Romani et al., 2015) . Vpr-mediated depletion of MUS81 and EME1 has been proposed to be a consequence of Vpr interaction with SLX4 (Laguette et al., 2014) , another proposed mechanism of Vpr-mediated G2/M arrest, although this is controversial (Berger et al., 2015; Fregoso and Emerman, 2016; Zhou et al., 2016) . In our system, of these three proteins (MCM10, MUS81, and EME1), only depletion of MCM10 showed a strong correlation with the extent of G2/M arrest caused by the different mutants ( Figure 5A ). As described previously (Romani et al., 2015) , depletion of MCM10 by RNAi was sufficient to cause accumulation of CEM-T4 T cells at G2/M ( Figures 5B and 5C ).
We therefore interrogated our Vpr mutant dataset (Figure 2 ) for other direct Vpr targets ( Table 1) that, like MCM10, correlated with the extent of G2/M arrest. In total, we identified 14 targets with a significant relationship (p < 0.05 in a linear regression analysis) ( Figure 5D ). Next we tested whether shRNA-mediated depletion could phenocopy Vpr-dependent cell cycle arrest at G2/M ( Figure 5D ). Depletion of 3 Vpr targets (SMN1, CDCA2, and ZNF267) caused G2/M arrest ( Figures 5D and 5E ). The correlation between G2/M arrest and depletion of these three proteins by Vpr mutants is shown in Figure 5F . The phenotype resulting from RNAi protein depletion was confirmed with a second shRNA ( Figure 5G ). Thus, several Vpr targets contribute independently to G2/M cell cycle arrest, consistent with a model whereby depletion of multiple cellular proteins underpins the various phenotypes associated with Vpr expression.
Some Vpr Targets Are Conserved across Primate Lentiviruses, but Global Cellular Proteome Remodeling Is Unique to the HIV-1/SIVcpz Lineage Targeting of key cellular proteins such as BST2 or the APOBEC3 family is conserved across multiple lentiviral lineages, demonstrating the in vivo selective advantage of these interactions. We therefore tested a diverse panel of lentiviral Vpr proteins to determine whether they share activity with the NL4-3 Vpr variant used in all of the experiments above. We included Vpr variants from primary isolates of HIV-1 from two distinct cross-species level classifications, shown here. Bars shown in red with a + symbol were enriched compared with the expected number through chance, whereas bars in blue (À) were de-enriched. Where p < 0.05, the associated p value represents the results of a Fisher's exact test with Bonferroni correction. transmissions from apes to humans (group M and group O), in addition to a closely related variant from Simian immunodeficiency virus (SIV) of chimpanzees (SIVcpz). We also tested Vpr variants from divergent primate lineages, including HIV-2, and SIVs from sooty mangabeys (SIVsmm), African green monkeys (SIVagm), and red-capped mangabeys (SIVrcm) (Figures 6A-6C ). In addition to Vpr, which is present in all primate lentiviruses, viruses of some lineages also bear Vpx, a gene duplication of Vpr. Because depletion of some substrates and cellular functions switches between Vpr and Vpx in lineages encoding this accessory gene (Fletcher et al., 1996; Lim et al., 2012) , we also included a Vpx variant from HIV-2.
Extensive Vpr-dependent remodeling of the cellular proteome was conserved across the HIV-1/SIVcpz lineage ( Figure 6D , top row). Although Vpr variants from other lineages showed a narrower set of changes, depletion of some proteins, particularly those most heavily depleted by HIV-1 Vpr, was conserved across multiple lineages ( overlapping panel of Vpr variants ( Figure 6E ). These conserved targets of direct Vpr-mediated degradation are likely to provide an in vivo replicative advantage for all primate lentiviruses.
Although the failure of SIVrcm, SIVagm, or SIVsmm Vpr variants to degrade proteins that are targeted by HIV-1/SIVcpz may be due to the use of human rather than cognate primate cells, it is Proteins previously predicted as potential Vpr targets because of a similar pattern of temporal regulation in HIV-1 infection . notable that HIV-2 Vpr did not cause global proteome remodeling, despite being tested in the host cell to which it is adapted.
Although none of the identified HIV-1 Vpr targets were degraded by the HIV-2 Vpx (HIV-2 ROD ) tested, we noted a shared ability of HIV-2 Vpx and SIVagm Vpr to deplete TASOR, a critical component of the human silencing hub (HuSH) transcription repressor complex (Tchasovnikarova et al., 2015;  Figure 7A ). While this manuscript was in preparation, two other groups independently discovered and reported Vpx-mediated depletion of TASOR (Chougui et al., 2018; Yurkovetskiy et al., 2018) . The HuSH complex mediates position-dependent transcriptional repression of a subset of lentiviral integrations, and we showed previously that antagonism of HuSH is able to potentiate HIV reactivation in the J-LAT model of latency (Tchasovnikarova et al., 2015) . As predicted, Vpx phenocopied the effect of RNAi-mediated TASOR depletion on reactivation of the HuSHsensitive J-LAT clone A1 ( Figure 7B ).
Previous reports (Chougui et al., 2018; Yurkovetskiy et al., 2018) were conflicted regarding the conservation of TASOR depletion across Vpr variants. With some exceptions, most primate lentiviruses can be categorized into 5 lineages ( Figure 7C ), two of which encode Vpx. The previously described canonical function of Vpx is degradation of SAMHD1 (Hrecka et al., 2011; Laguette et al., 2011) . Two lentiviral lineages lack Vpx but use Vpr to degrade SAMHD1, whereas the HIV-1/SIVcpz lineage lacks SAMHD1 antagonism (Lim et al., 2012) . We considered that TASOR antagonism may follow the same pattern and thus tested Vpx proteins from both Vpx-bearing lineages and representative Vpr variants from lineages that use Vpr to degrade SAMHD1. All of these proteins were able to deplete TASOR in Vpx/Vpr-transduced cells ( Figure 7D) , and, therefore, antagonism of SAMHD1 and TASOR appears to follow the same pattern.
Although the targeting of some substrates was conserved across Vpr variants from multiple lineages, we did not observe broad proteome remodeling outside of the HIV-1/SIVcpz lineage. However, in the experiment described in Figure 6A , an HIV-1-based lentiviral transduction system was used. Of the Vpr and Vpx variants tested, only Vpr proteins from the HIV-1/ SIVcpz alleles are efficiently packaged into the virion. In these cases, cells receive both incoming and de novo-synthesized Vpr, whereas, in the case of other variants tested, only de novo-synthesized Vpr is present. Therefore, there is a time lag of 18-24 h for viral entry, reverse transcription, integration, and de novo synthesis of protein to begin. The more limited proteome remodeling seen in Vpr variants could reflect a lack of time for such changes to occur.
To account for this, we carried out an experiment in which cells were transduced with Vpr or Vpx from the primary HIV-2 isolate 7312a and assayed 48-96 h post-transduction ( Figure 7E ), allowing time for additional changes to develop after de novo Vpr/Vpx synthesis. Even 96 h after transduction, HIV-2 Vpr showed very limited changes. The majority of these changes consisted of depletion of proteins also targeted by HIV-1 Vpr ( Figure 7F, left panel) . Curiously, 7312a HIV-2 Vpx also depleted several proteins modulated by HIV-1 Vpr ( Figure 7F , right panel), including direct targets for HIV-1 Vpr-mediated degradation, BBX, HASPIN, and ARHGAP11A. Some proteins were degraded by both HIV-2 Vpr and Vpx, whereas others were only degraded by the Vpx of this isolate. In lentiviral strains and/or lineages that encode both Vpr and Vpx, the responsibility for degrading certain targets of HIV-1 Vpr is therefore shared between Vpr and Vpx, further emphasizing their in vivo importance.
Conversely, global proteome remodeling does not occur from extended expression of HIV-2 Vpr or Vpx. The difference between HIV-1 and HIV-2 Vpr in this respect may contribute, in part, to the increased pathogenicity of HIV-1 in humans over HIV-2 (Jaffar et al., 2004) , particularly given the potential for HIV-1 Vpr to drive these changes in Vpr-exposed but uninfected bystander cells.
DISCUSSION
Proteomics analyses of cells infected with viruses from different orders have revealed widespread and varied changes to the cellular proteome (Diamond et al., 2010; Ersing et al., 2017; Greenwood et al., 2016; Weekes et al., 2014) . Although these changes are presumed to be multifactorial, in the case of HIV-1 infection, our data show that the majority of changes can be attributed to the action of a single viral protein, Vpr. We propose that this global cellular proteome remodeling consists of direct targeting of multiple cellular proteins for proteasomal degradation via the DCAF1/DDB1/CUL4A E3 ligase complex, followed by resulting secondary effects on other proteins. Although many of the changes caused by Vpr are secondary, they occur within the physiological time frame of productive infection (Murray et al., 2011; Perelson et al., 1996) and are therefore relevant to our understanding of the HIV-1-infected cell. Further, we have recently mapped changes to the cellular proteome in HIV-1-infected primary human CD4+ T cells and confirmed that the Vpr-mediated changes described here in CEM-T4s are recapitulated in the natural cell type of HIV infection (Naamati et al., 2019) .
Before this study, the list of direct Vpr targets was already extensive. Here we confirmed Vpr-mediated depletion of the previously described Vpr targets HLTF (Hrecka et al., 2016; Lahouassa et al., 2016) , ZGPAT (Maudet et al., 2013) , MCM10 (Romani et al., 2015) , UNG2 (Schrö felbauer et al., 2005) , TET2 (Lv et al., 2018) , and MUS81 and EME1 (Laguette et al., 2014; Zhou et al., 2016) , whereas SMUG1 (Schrö felbauer et al., 2005) and PHF13 (Hofmann et al., 2017) were not detected in our model T cell line. By analogy with other HIV accessory proteins, it might have been predicted that this list of Vpr targets would be nearly complete. Instead, we show here that it is only the tip of the iceberg.
Although surprising, the ability of Vpr to degrade multiple cellular factors may be explained by the biology of this small protein. Mechanistically, depletion of multiple proteins with nucleic acid binding properties is consistent with known structural determinants of Vpr substrate recruitment. From a functional viewpoint, although HIV-1 has three accessory proteins (Vpu, Nef, and Vif) to aid viral replication and counteract host defenses in the late stages of the viral replication cycle, Vpr is the only HIV-1 accessory protein packaged into virions. Multiple targets may therefore be required to protect incoming virions from cellular factors and to prime newly infected cells for productive viral replication.
This work is not the first attempt to use unbiased proteomics analysis to characterize Vpr function. Previous studies have used single proteomics experiments or methods to identify candidate proteins that either interact with or are depleted by Vpr, with individual proteins followed up using targeted immunoreagents. For example, Vpr binding partners were identified by Jä ger et al. (2011) and Hrecka et al. (2016) using IP-MS. Jä ger et al. (2011) did not determine whether any of these proteins were depleted, whereas Hrecka et al. (2016) focused on the single target protein, HLTF and found it to be depleted by Vpr. Similarly, Lahouassa et al. (2016) used a SILAC-based approach to quantify proteomic changes in cells exposed to viral particles bearing Vpr, identifying 8 proteins that were depleted by at least 20%. Of these, only one, HLTF, was confirmed to be a direct Vpr target by targeted orthogonal approaches.
As expected, the lists of ''candidate'' Vpr proteins identified but not pursued in the above studies overlaps with this work, and, in some instances, we confirmed these candidates to be direct targets for Vpr-mediated degradation. For example, SMN1 was found to bind Vpr by Jä ger et al. (2011) and to be degraded by Vpr by Lahouassa et al. (2016) in independent proteomics experiments. Similarly, ESCO2 was found to bind Vpr by Hrecka et al. (2016) , but the depletion was not confirmed by immunoblot, most likely because of poor performance of the commercial antibody used. We have shown here that both of these proteins are direct targets for Vpr-mediated degradation. 
Defined here as a log 2 fold change of less than À1 compared with the empty vector (50% reduction).
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In contrast to previous studies, rather than using a targeted approach to follow up only a small number of potential Vpr targets, we combined complementary proteomics analyses to describe the global proteome remodeling caused by Vpr and multiple direct substrates for Vpr-mediated depletion. The two established criteria for Vpr targets (binding and destabilization) are satisfied by numerous proteins identified here, including ESCO2, SMN1, BBX, and KIF18A. These proteins are therefore not candidate Vpr targets, but bona fide Vpr targets, proven to the same standard of evidence as other, previously described substrates.
However, in our proposed model, Vpr binds and degrades multiple cellular proteins, with the total pool of Vpr shared over multiple targets. Therefore, identification of cellular targets by coIP is technically problematic and more prone to false negatives compared with other proteins that establish interactions with a small number of binding partners. We therefore used an alternative method of identifying direct targets for Vpr-mediated depletion: proteins that are post-translationally degraded within 6 h of treatment with Vpr. We are confident that the other proteins identified in this fashion also represent direct targets for Vpr-mediated degradation because secondary effects are excluded by both intrinsic elements of the technique and the short time frame allowed.
Despite the importance of Vpr in vivo, a positive in vitro viral replication phenotype is often absent in T cell infection models (Goh et al., 1998; Guenzel et al., 2014) . Nonetheless, expression of Vpr in T cells causes cell cycle arrest (Bolton and Lenardo, 2007; Gummuluru and Emerman, 1999; Rogel et al., 1995) ; cell death (Bolton and Lenardo, 2007) ; transactivation of the viral LTR (Gummuluru and Emerman, 1999) ; enhancement or antagonism of crucial signaling pathways, including NFAT (Hö hne et al., 2016) and NF-kB (Liang et al., 2015; Liu et al., 2014; Muthumani et al., 2006) ; disruption of PARP1 localization (Hö hne et al., 2016; Muthumani et al., 2006) ; defects in chromatid cohesion (Shimura et al., 2011) ; and induction of the DNA damage response Vassena et al., 2013) . At least some of these phenotypes can be segregated (Bolton and Lenardo, 2007; Hö hne et al., 2016) . The molecular mechanisms underpinning these phenomena have remained controversial. In our model, these multiple phenotypes can be explained by Vpr targeting multiple cellular proteins and pathways with potential for redundant or cumulative effects.
Here we considered the most well-described cellular phenotype for Vpr, G2/M cell cycle arrest, with findings compatible with this model. In addition to confirming the previously described effect of Vpr-mediated MCM10 degradation, we identified three other proteins that are directly targeted by Vpr, show depletion correlating with the extent of G2/M-mediated arrest in a panel of Vpr mutants, and result in arrest at G2/M when depleted through RNAi. Notably, depletion of two of these proteins, SMN1 and CDCA2 (Repo-Man), has been shown to activate the DNA damage response and stimulate ATM and/or ATR kinase activity (Kannan et al., 2018; Peng et al., 2010) , a critical step toward G2/M arrest caused by Vpr (Berger et al., 2015; Fregoso and Emerman, 2016; Roshal et al., 2003) . The contribution of multiple Vpr targets to the same cellular phenotype may also be exemplified by another described cellular phenotype for Vpr, premature chromatid segregation (PCS) (Shimura et al., 2011) . Although not specifically investigated here, RNAimediated knockdown of three proteins depleted by Vpr-ESCO2, CDCA5 (Sororin), and HASPIN-has been associated previously with this phenotype in different systems (Dai et al., 2006; Hou and Zou, 2005; Rankin et al., 2005) .
In conclusion, Vpr degrades multiple cellular targets, resulting in global remodeling of the host proteome and labyrinthine changes to different cellular pathways. This explains why its effects on cellular phenotypes and viral replication are complex and remain poorly understood, why the functional consequences of individual Vpr targets identified and studied in isolation have proved elusive, and why the search for a single critical Vpr target has been problematic.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: (Foley et al., 1965) and J-LAT A1 (male) T cells (AIDS Reagent Program, Division of AIDS, NIAD, NIH: Dr E Verdin, (Jordan et al., 2003; Jordan et al., 2001) were cultured in RPMI supplemented with 10% FCS, 100 units/ml penicillin and 0.1 mg/ml streptomycin at 37 C in 5% CO2. HEK293T (female) embryonic kidney cells (Lehner laboratory stocks) were cultured in DMEM supplemented with 10% FCS, 100 units/ml penicillin and 0.1 mg/ml streptomycin at 37 C in 5% CO2. All cells were confirmed to be mycoplasma negative (MycoAlert, Lonza).
METHOD DETAILS
NL4-3 molecular clones pNL4-3-dE-EGFP (derived from the HIV-1 molecular clone pNL4-3 but encoding Enhanced Green Fluorescent Protein (EGFP) in the env open reading frame (ORF), rendering Env non-functional) was obtained through the AIDS Reagent Program, Division of AIDS, NIAD, NIH: Drs Haili Zhang, Yan Zhou, and Robert Siliciano (Zhang et al., 2004) and the complete sequence verified by Sanger sequencing. The DVpr mutant was generated by cloning three stop codons into the Vpr open reading frame, immediately after the overlap with Vif to prevent interference with that gene: WT Vpr ORF sequence ATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCATACAATGAATGGACACTAGAGCTTTTAGAGGAA. DVpr ORF sequence ATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCATACAATGAATGGACACTAGAGCTTTAATAGTAA
Viral stocks
VSVg-pseudotyped NL4-3-dE-EGFP HIV viral stocks were generated by co-transfection with pMD.G (VSVg) as previously described . NL4-3-dE-EGFP HIV viral stocks were titerd by infection/transduction of known numbers of relevant target cells under standard experimental conditions followed by flow cytometry for GFP and CD4, using Anti-CD4-AF647 (clone OKT4; BioLegend) at 48 hr to identify % infected cells. Single Vpr and Vpx proteins were expressed in a modified dual promotor pHRSIN (van den Boomen et al., 2014) vector in which Vpr or Vpx expression is driven by the rous sarcoma virus (RSV) promotor, and Emerald GFP expression is driven by the ubiquitin promotor. Virus was generated by co-transfection with pCMVdr8.91 and pMD.G (Zufferey et al., 1997 ) in 293T as previously described . Infectious MOI was normalized by infection in the absence of reverse transcription (RTi) inhibitors, which were included where specified (see below). GenBank accession numbers of the untagged sequences for the Vpr and Vpx proteins used are given in the Key Resources Table. Amino acid sequences were codon optimized, modified to include a HA tag, and synthesized as double stranded DNA (IDT), inserted into the empty vector construct by Gibson assembly, and confirmed by sanger sequencing.
Lentivector for shRNA expression For lentiviral DCAF1 shRNA-mediated knockdown, hairpins were cloned into pHRSIREN-PGK-hygro, with transduced cells selected for hygromycin resistance. The same methodology was used to clone other target shRNA haripins, into pHRSIREN-PGK-puro (encoding puromycin resistance). Gene specific target sequences were chosen from the Broad institute GPP web portal, and are provided in the forward orientation in the Key Resources Table. CEM-T4 T cell infections CEM-T4 T cells were infected with concentrated NL4-3-dE-EGFP or pHRSIN lentiviral stocks by spinoculation at 800 3 g for 1 h in a non-refrigerated benchtop centrifuge in complete media supplemented with 10 mM HEPES. Where reverse transcription treatment was specified (RTi), cells were incubated with zidovudine (10 mM) and efavirenz (100 nM) (AIDS Reagent Program, Division of AIDS, NIAD, NIH) for 1 hr prior to spinoculation, and inhibitors maintained at these concentrations during subsequent cell culture. For MS experiments, cells were subject to dead cell removal (magnetic dead cell removal kit, Miltenyi). Subsequent sample preparation, TMT labeling, and MS are described below, at the end of this section.
Immunoblotting
Antibodies against the following proteins were used for immunoblot, listed by manufacturer: Atlas antibodies: TASOR (HPA006735). Bethyl: BBX (A303-151A), HLTF (A300-230A), RALY (A302-070A), ZNF512B (A303-234A). Cell Signaling Technology: SMN1/2 (2F1). Novus: ESCO2 (NB100-87021). Origene: UNG2 (2C12). Proteintech: Vpr (51143-I-AP). Santa Cruz: CCNB1 (SC-245), ZGPAT (SC-515524). Sigma: b-actin (AC74). Abcam: p24 (ab9071), VCP (ab11433). The following secondary antibodies were used: goat anti-mouse-HRP and goat anti-rabbit-HRP (immunoblot, Jackson ImmunoResearch, West Grove, PA). Blots were immersed in chemiluminescent substrate (SuperSignal West Pico or Dura, Thermo Fisher Scientific), and signal was visualized using X-ray film or the iBright CL1000 imaging system (Thermo Fisher Scientific).
ShRNA knockdown confirmation by RT-PCR Total RNA was extracted using the RNeasy Plus Mini kit (QIAGEN). Total RNA (250 ng) was reverse transcribed into cDNA using a poly(d)T primers and SuperScript III Reverse Transcriptase (Invitrogen) following the manufacturer's instructions. Real-time qRT-PCR was performed using the ABI 7500 Real-Time PCR system (Applied Biosystems) and SYBR Green PCR Master Mix (Applied Biosystems), with cycling parameters of 50 C for 2 min and 95 C for 5 min, followed by 40 cycles of 95 C for 15 s and 60 C for 1 min. The gene-of-interest specific primer pairs were predesigned and purchased from Sigma-Aldrich as KiCqStart primers. The sequences are detailed in the key resources table. The difference in the amount of input cDNA was normalized to an internal control of GAPDH (Cano et al., 2015) .
7-AAD staining
Cells were fixed in ice cold 70% ethanol for at least 30 minutes, washed with PBS and stained in 25ug/ml 7-AAD for 15 minutes before acquisition on a BD FACSCalibur. Analysis was carried out in Flowjo, v.10.5.2. Dead cells and doublets were excluded by gating on forward scatter, side scatter, and fluorescent area and height. Univariate cell cycle modeling was carried out using the Watson pragmatic method in Flowjo.
Immunoprecipitation Mass spectrometry (IP-MS)
Prior to infection with Vpr positive or negative lentivirus, CEM-T4 T cells were treated for two hours with the pan-cullin inhibitor MLN4924, 500nm (Millipore). 24 hours post infection, cells were lysed in 1% NP-40 (IGEPAL CA-630, Sigma-Aldrich), with benzonase (Sigma-Aldrich) at 2000 units/ml. Lysates were pre-cleared with IgG-Sepharose (GE Healthcare, UK) and incubated for 3 hr at 4 C with anti-HA coupled to agarose beads (EZview Red Anti-HA Affinity Gel, Sigma-Aldrich). After washing in 0.5% NP-40, samples were eluted with 0.5 mg/ml HA peptide (Sigma-Aldrich) at 37 C for 1 hr. Proteins defined as co-immunoprecipitating with Vpr were detected with at least 3 peptides in the Vpr condition, not identified in the control condition, and were present in < 20% of IP-MS available in the Crapome v1.1 database (Mellacheruvu et al., 2013) . pH8 and 0.1% Sodium deoxycholate (SDC) is then added to the washed beads along with trypsin. Samples were then incubated overnight at 37 degrees with periodic shaking at 2000rpm. After digestion, peptides are immobilised on beads by addition of 200-400uL ACN and washed twice with 100uL ACN before eluting in 19uL 2% DMSO and removing the eluted peptide from the beads.
Offline high pH reversed-phase (HpRP) peptide fractionation For whole cell proteome samples HpRP fractionation was conducted on an Ultimate 3000 UHPLC system (Thermo Scientific) equipped with a 2.1 mm 3 15 cm, 1.7m Aqcuity BEH C18 column (Waters, UK). Solvent A was 3% ACN, Solvent B was 100% ACN, solvent C was 200 mM ammonium formate (pH 10). Throughout the analysis solvent C was kept at a constant 10%. The flow rate was 400 mL/min and UV was monitored at 280 nm. Samples were loaded in 90% A for 10 min before a gradient elution of 0%-10% B over 10 min (curve 3), 10%-34% B over 21 min (curve 5), 34%-50% B over 5 mins (curve 5) followed by a 10 min wash with 90% B. 15 s (100 mL) fractions were collected throughout the run. Peptide containing fractions were orthogonally recombined into 24 fractions (i.e., fractions 1, 25, 49, 73, 97 combined) and dried in a vacuum centrifuge. Fractions were stored at À80 C prior to analysis.
Mass spectrometry
Data were acquired on an Orbitrap Fusion mass spectrometer (Thermo Scientific) coupled to an Ultimate 3000 RSLC nano UHPLC (Thermo Scientific). HpRP fractions were resuspended in 20 ml 5% DMSO 0.5% TFA and 10uL injected. Fractions were loaded at 10 ml/min for 5 min on to an Acclaim PepMap C18 cartridge trap column (300 um 3 5 mm, 5 um particle size) in 0.1% TFA. After loading a linear gradient of 3%-32% solvent B was used for sample separation over a column of the same stationary phase (75 mm 3 50 cm, 2 mm particle size) before washing at 90% B and re-equilibration. Solvents were A: 0.1% FA and B:ACN/0.1% FA. 3h gradients were used for whole cell proteomics samples, 1h gradients for IP-MSs.
An SPS/MS3 acquisition was used for TMT experiments and was run as follows. MS1: Quadrupole isolation, 120'000 resolution, 5e5 AGC target, 50 ms maximum injection time, ions injected for all parallelisable time. MS2: Quadrupole isolation at an isolation width of m/z 0.7, CID fragmentation (NCE 35) with the ion trap scanning out in rapid mode from m/z 120, 8e3 AGC target, 70 ms maximum injection time, ions accumulated for all parallelisable time. In synchronous precursor selection mode the top 10 MS2 ions were selected for HCD fragmentation (65NCE) and scanned out in the orbitrap at 50'000 resolution with an AGC target of 2e4 and a maximum accumulation time of 120 ms, ions were not accumulated for all parallelisable time. The entire MS/MS/MS cycle had a target time of 3 s. Dynamic exclusion was set to ± 10 ppm for 90 s, MS2 fragmentation was trigged on precursor ions 5e3 counts and above. For IP-MS, MS2 instead used HCD fragmentation (NCE 34) and a maximum injection time of 250ms and had a target cycle time of 2 s. For pSILAC MS1 was acquired at 240'000 resolution.
QUANTIFICATION AND STATISTICAL ANALYSIS
Description of statistical tests and n values are provided in the figure legends. Anova and Fisher's exact test analysis were carried out as described in figure legends using Graphpad Prism (v7.04).
Gene ontology enrichment
Gene ontology enrichment analysis was carried out using the statistical overrepresentation test of PANTHER (release 10/10/2018) (Mi et al., 2017) , using the web interface at: http://www.pantherdb.org/, and using the GO Ontology database (release 06/09/2018), (Ashburner et al., 2000; The Gene Ontology Consortium, 2019) . Lists of proteins highly significantly depleted or increased by Vpr were compared to a background list of proteins quantitated in the two experiments used to define those lists. p values shown are the results of a Fisher's exact test with Bonferroni correction. In the case of GO: Cellular compartment analysis, this is highly conservative as it is corrected for all 1061 possible cellular compartment terms, not just those curated. When calculating the proportion of proteins with a specific GO term, only proteins with a GO term of that class were included in the denominator.
MS Data processing and analysis
For TMT labeled samples data were searched by Mascot within Proteome Discoverer 2.1 in two rounds of searching. First search was against the UniProt Human reference proteome (26/09/17) (UniProt Consortium, 2019), the HIV proteome and compendium of common contaminants (GPM). The second search took all unmatched spectra from the first search and searched against the human trEMBL database (Uniprot, 26/09/17). The following search parameters were used. MS1 Tol: 10 ppm, MS2 Tol: 0.6 Da. Enzyme: Trypsin (/P). MS3 spectra were used for reporter ion based quantitation with a most confident centroid tolerance of 20 ppm. PSM FDR was calculated using Mascot percolator and was controlled at 0.01% for 'high' confidence PSMs and 0.05% for 'medium' confidence PSMs. Normalization was automated and based on total s/n in each channel. Protein/peptide abundance was calculated and output in terms of 'scaled' values, where the total s/n across all reporter channels is calculated and a normalized contribution of each channel is output. Proteins/peptides satisfying at least a 'medium' FDR confidence were taken forth to statistical analysis in R (v3.3.1) (R Core Team, 2013) . This consisted of a moderated t test (Limma) with Benjamini-Hochberg correction for multiple hypotheses to provide a q value for each comparison (Huber et al., 2015; Schwä mmle et al., 2013) . IP-MS were submitted to a similar search workflow with quantitative data being derived from MS1 spectra via proteome discover minora feature detector node. For pSILAC experiments data were processed in MaxQuant and searched using Andromeda with similar search parameters (Cox and Mann, 2008) . MaxQuant output was uploaded into Perseus for calculation of significance B (Tyanova et al., 2016) . Where conditions were not carried out in triplicate, downstream analysis was limited to proteins identified with at least 3 unique peptides.
Phylogenetic tree of Vpr sequences An existing nucleic acid sequence alignment of representative Vpr sequences from HIV-1, HIV-2 and SIVs from 22 primate species was downloaded from the Los Alamos National Laboratories HIV database (https://hiv.lanl.gov/content/sequence/NEWALIGN/align. html). A tree was generated using the percentage identity average distance in jalview (Waterhouse et al., 2009 ) and visualized in Figtree (http://tree.bio.ed.ac.uk/software/figtree). Sequences from 5 primate species not falling into the highlighted linages are not shown. Cercopithecus lineage includes closely related viruses from primates of the Miopithecus and Piliocolobus genera.
DATA AND SOFTWARE ANALYSIS
In addition to Table S1 , which includes data from all of the proteomics experiments carried out here, proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaíno et al., 2016) partner repository. The accession number for the data reported in this paper is PRIDE: PXD013221.
